ENTPD2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL13210969	1.00	3/20
SCHEMBL13210978	1.00	3/20
SCHEMBL13210980	1.00	3/20
SCHEMBL14384424	1.00	3/20
SCHEMBL14384565	1.00	3/20
SCHEMBL13210979	0.90	3/20
SCHEMBL13210974	0.85	3/20
SCHEMBL13210981	0.85	3/20
SCHEMBL13210968	0.85	3/20
SCHEMBL14384425	0.85	3/20
SCHEMBL13210975	0.83	3/20
SCHEMBL3023054	0.79	3/20
SCHEMBL3023058	0.79	3/20
SCHEMBL3020107	0.79	3/20
SCHEMBL3020110	0.79	3/20
SCHEMBL13211022	0.79	3/20
SCHEMBL15859417	0.79	3/20
SCHEMBL15859418	0.79	3/20
SCHEMBL3020850	0.78	3/20
SCHEMBL3020853	0.78	3/20

Clinical trials — most relevant to ENTPD2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Daratumumab Intensified Treatment to Eligible MM New Patients CTD-Dara Induction, Follow by Dara Consolidation	PHASE3	UNKNOWN
Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer	PHASE2	RECRUITING
Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia	PHASE1/PHASE2	COMPLETED
A Study of ES002023 (Anti-CD39 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors	PHASE1	COMPLETED
A Study of ES014 (Anti-CD39/TGF-β Bispecific Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors	PHASE1	WITHDRAWN
Vatalanib and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Pharmacokinetics of Plasma Doravirine Once Daily Over 72 Hours Following Drug Intake Cessation in Healthy Volunteers	PHASE1	COMPLETED
A Randomized Controlled Trial of Topical 5% Niacinamide for Skin Cancer Prevention in Transplant Recipients	EARLY_PHASE1	RECRUITING
Diadenosine Polyphosphates and Mucin Associated With Ocular Surface Disorders	nan	UNKNOWN
Genetic Characterization of Parkinson's Disease	nan	COMPLETED
PCD New Gene Discovery	nan	COMPLETED
Genetic Feature of Congenital Hearing Loss in Chinese Population	nan	NOT_YET_RECRUITING
Genetics of Middle Ear Disease	nan	COMPLETED
Celiac Disease Genomic Environmental Microbiome and Metabolomic Study	nan	RECRUITING
Pathophysiology of Paget's Disease of Bone	nan	COMPLETED
Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts	nan	COMPLETED
Study of People With Generalized Arterial Calcification of Infancy (GACI) or Autosomal Recessive Hypophosphatemic Rickets Type 2 (ARHR2)	nan	COMPLETED
A Phase I Trial of AVN944, an IMPDH Inhibitor, in Adults With Advanced Stage Solid Tumors	nan	WITHDRAWN
Genome Environment Microbiome and Metabolome in Autism Study	nan	COMPLETED
A Natural History Study Seeks to Understand the Clinical, Genomic, Pharmacological, Laboratory, and Dietary Determinates of Pyrimidine and Purine Metabolism Disorders	nan	RECRUITING
Genes Involved in Resistance or Susceptibility to Hepatitis B Virus	nan	COMPLETED
Epigenetics, DNA Methylation Patterns and Periodontal Disease	nan	COMPLETED
MNGIE Natural History Study	nan	RECRUITING
miRNAs Profiling in Parkinson's Disease	nan	COMPLETED
Genetics of Primary Ciliary Dyskinesia	nan	COMPLETED
Role of A Disintegrin and Metalloproteinase (ADAM) in Epithelial Dysfunction	nan	COMPLETED
Genetic Risk of Osteonecrosis of the Jaw (ONJ) in Patients With Metastatic Cancer: Concordance Study	nan	COMPLETED
EXtremely Early-onset Type 1 Diabetes EXtremely Early-onset Type 1 Diabetes (A Musketeers' Memorandum Study)	nan	RECRUITING
Histoblood Group Antigens as a Risk Factor of Asthma	nan	COMPLETED
Institution of an Italian Multicenter Database of Patients Affected by Diseases of Phosphate Metabolism	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a ENTPD2 binder may also engage these)

Protein	Name	Similarity
O35795	—	1.000	O35795 →
O55026	—	0.992	O55026 →
ENTPD8	Ectonucleoside triphosphate diphosphohydrolase 8	0.991	landscape →
A0JND9	—	0.987	A0JND9 →
Q5DRK1	—	0.982	Q5DRK1 →
Q8K0L2	—	0.973	Q8K0L2 →
O93295	—	0.968	O93295 →
Q0VD19	—	0.962	Q0VD19 →
SMPD1	Sphingomyelin phosphodiesterase	0.960	landscape →
Q9WUZ9	—	0.958	Q9WUZ9 →
P79784	—	0.958	P79784 →
Q9QYC8	—	0.958	Q9QYC8 →
Q3U0P5	—	0.957	Q3U0P5 →
HDAC10	Polyamine deacetylase HDAC10	0.957	landscape →
P97687	—	0.956	P97687 →
Q04519	—	0.956	Q04519 →
Q32M88	—	0.956	Q32M88 →
ITGA5	Integrin alpha-5	0.955	landscape →
Q6P6S9	—	0.955	Q6P6S9 →
Q8BP56	—	0.955	Q8BP56 →
D3YTS9	—	0.955	D3YTS9 →
Q0P5F0	—	0.955	Q0P5F0 →
Q9BZG2	—	0.954	Q9BZG2 →
Q9MYU4	—	0.954	Q9MYU4 →
Q9EQV6	—	0.954	Q9EQV6 →
Q5NVF6	—	0.953	Q5NVF6 →
Q9QXE5	—	0.953	Q9QXE5 →
P56433	—	0.953	P56433 →
O09008	—	0.953	O09008 →
Q9NPR2	—	0.953	Q9NPR2 →